Currency In USD
| Previous Close | 4.3 |
| Open | 4.04 |
| Day High | 4.13 |
| Day Low | 3.73 |
| 52-Week High | 5.91 |
| 52-Week Low | 2.67 |
| Volume | 4.14M |
| Average Volume | 4.35M |
| Market Cap | 730.04M |
| PE | -3.8 |
| EPS | -1.06 |
| Moving Average 50 Days | 3.68 |
| Moving Average 200 Days | 3.5 |
| Change | -0.28 |
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 07, 2026 1:00 PM GMT
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chie
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
GlobeNewswire Inc.
Dec 07, 2025 1:05 PM GMT
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the publication of Phase 1/2
Prime Medicine to Present at 8th Annual Evercore Healthcare Conference
GlobeNewswire Inc.
Nov 25, 2025 1:00 PM GMT
CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chie